Table 1 The clinical characteristics in all NTRK fusion-positive and NTRK fusion-negative cohorts.
From: Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China
|  | Overall (N = 10,194) | NTRK fusion-positive (N = 40) | NTRK fusion-negative (N = 10,154) | P-value |
|---|---|---|---|---|
Age, median (range), years | 58.0 [1.0, 96.0] | 45.0 [≤1.0, 76.0] | 58.0 [1.00, 96.0] | <0.001 |
 Infantile (≤1), n (%) | 12 (0.1%) | 4 (10.0%) | 8 (0.1%) |  |
 Pediatric (>1 to ≤18), n (%) | 157 (1.5%) | 6 (15.0%) | 151 (1.5%) |  |
 Adult (>18), n (%) | 10,025 (98.3%) | 30 (75.0%) | 9995 (98.4%) |  |
Gender | Â | Â | Â | 0.79 |
 Female | 4039 (39.6%) | 15 (37.5%) | 4024 (39.6%) |  |
 Male | 6155 (60.4%) | 25 (62.5.0%) | 6130 (60.4%) |  |
Tumor stage, n (%) | Â | Â | Â | 0.64 |
 I-II | 3571 (35%) | 11 (27.5%) | 3560 (35.1%) |  |
 III-IV | 5652 (55.4%) | 23 (57.5%) | 5629 (55.4%) |  |
 Unknown | 971 (9.5%) | 6 (15.0%) | 965 (9.5%) |  |
TMB, median (range), muts/Mb | 4.60 [0.00, 825] | 3.80 [0.0, 180] | 4.60 [0.00, 825] | 0.19 |
MSI status, n (%) | Â | Â | Â | <0.001 |
 MSI-H | 186 (1.8%) | 6 (15.0%) | 180 (1.8%) |  |
 MSS | 9461 (92.8%) | 32 (80.0%) | 9429 (92.9%) |  |
 Unknown | 547 (5.4%) | 2 (5.0%) | 545 (5.4%) |  |
Tumor_type, n (%) | Â | Â | Â | <0.001 |
 Soft tissue sarcoma | 571 (5.6%) | 17 (45.5%) | 554 (5.5%) |  |
 Colorectal cancer | 1225 (12.0%) | 7 (17.5%) | 1218 (12.0%) |  |
 Non-small cell lung cancer | 2039 (20.0%) | 5 (12.5%) | 2034 (20.0%) |  |
 Hepatocellular carcinoma | 1133 (11.1%) | 2 (5.0%) | 1131 (11.1%) |  |
 Breast cancer | 323 (3.2%) | 1 (2.5%) | 322 (3.2%) |  |
 Small cell lung cancer | 220 (2.2%) | 2 (5.0%) | 218 (2.1%) |  |
 Extrahepatic cholangiocarcinoma | 351 (3.4%) | 1 (2.5%) | 350 (3.4%) |  |
 Head and neck carcinoma | 175 (1.7%) | 1 (2.5%) | 174 (1.7%) |  |
 Intrahepatic cholangiocarcinoma | 555 (5.4%) | 1 (2.5%) | 554 (5.5%) |  |
 Ovarian cancer | 261 (2.6%) | 1 (2.5%) | 260 (2.6%) |  |
 Gastric cancer | 866 (8.5%) | 1 (2.5%) | 865 (8.5%) |  |
 Thyroid tumor | 32 (0.3%) | 1 (2.5%) | 31 (0.3%) |  |
 Gallbladder carcinoma | 240 (2.4%) | 0 (0%) | 240 (2.4%) |  |
 Bone sarcoma | 183 (1.8%) | 0 (0%) | 183 (1.8%) |  |
 Cancer of unknown primary | 120 (1.2%) | 0 (0%) | 120 (1.2%) |  |
 Endocervical carcinoma | 104 (1.0%) | 0 (0%) | 104 (1.0%) |  |
 Endometrial carcinoma | 61 (0.6%) | 0 (0%) | 61 (0.6%) |  |
 Esophageal carcinoma | 610 (6.0%) | 0 (0%) | 610 (6.0%) |  |
 Gastrointestinal neuroendocrine tumor | 74 (0.7%) | 0 (0%) | 74 (0.7%) |  |
 Melanoma | 59 (0.6%) | 0 (0%) | 59 (0.6%) |  |
 Pancreatic cancer | 498 (4.9%) | 0 (0%) | 498 (4.9%) |  |
 Renal cell carcinoma | 308 (3.0%) | 0 (0%) | 308 (3.0%) |  |
 Small bowel carcinoma | 57 (0.6%) | 0 (0%) | 57 (0.6%) |  |
 Thymic tumor | 33 (0.3%) | 0 (0%) | 33 (0.3%) |  |
 Urothelial carcinoma | 96 (0.9%) | 0 (0%) | 96 (0.9%) |  |
